RLYB News and Press, Rallybio Corporation From 05/08/25

Ironwood Pharmaceuticals Inc. (IRWD) is expected to report $-0.05 for Q1 2025 CaliberCos Inc. (CWD) is expected to report $-0.4 for Q1 2025 BlackRock TCP Capital Corp. (TCPC) is expected to report $0.34 for Q1 2025 INmune Bio Inc. (INMB) is expected to report $-0.43 for Q1 2025 No...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will participate in a fireside chat ...

– RLYB212 Phase 2 PK Results Did Not Achieve Target Concentrations, Including Minimum Target Concentration Required for Efficacy – – RLYB116 Confirmatory PK/PD Study to Initiate in 2Q 2025, with Data in 2H 2025 – Rallybio Corporation (Na...

2025-03-13 09:25:34 ET More on Rallybio Seeking Alpha’s Quant Rating on Rallybio Historical earnings data for Rallybio Financial information for Rallybio Read the full article on Seeking Alpha For further details see: Rallybio GAAP EPS of $...

— Key Data Readouts from Sentinel Participant in RLYB212 Phase 2 Clinical Trial Expected in 2Q 2025 and 3Q 2025 — — Initiation of RLYB116 Confirmatory PK/PD Study Expected in 2Q 2025, with Data Anticipated in 2H 2025 — — $65.5 Million in Cash, Ca...

Algoma Steel Group Inc. (ASTL) is expected to report $0.06 for Q3 2025 E.W. Scripps Company (The) (SSP) is expected to report for Q4 2024 TransAct Technologies Incorporated (TACT) is expected to report $-0.1 for Q4 2024 Kindly MD, Inc. (KDLY) is expected to report for Q4 2024 Talo...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will present a corporate overview at...

– Key Data Readouts from Sentinel Participant Expected in 2Q 2025 and 3Q 2025 – Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today an...

– Dosing of Sentinel (First) Participant in RLYB212 Phase 2 Clinical Trial Expected in 2Q 2025 – – Initiation of RLYB116 Confirmatory PK/PD Study Expected in 2Q 2025, with Data Anticipated in 2H 2025 – – REV102, an ENPP1 Inhibitor for the Treatme...